期刊
FUTURE ONCOLOGY
卷 19, 期 30, 页码 2055-2073出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2023-0227
关键词
ADT; androgen receptor; CRPC; CSPC; prostate cancer; siRNA
类别
This review discusses the development of castration-resistant prostate cancer (CRPC) as a result of androgen deprivation therapy, and highlights the limitations of current treatments targeting the androgen receptor (AR). The use of small interfering RNAs (siRNAs) as a targeted therapy for CRPC is proposed as a promising strategy.
Androgen deprivation therapy is a common treatment method for metastatic prostate cancer through lowering androgen levels; however, this therapy frequently leads to the development of castration-resistant prostate cancer (CRPC). This is attributed to the activation of the androgen receptor (AR) signaling pathway. Current treatments targeting AR are often ineffective mostly due to AR gene overexpression and mutations, as well as the presence of splice variants that accelerate CRPC progression. Thus there is a critical need for more specific medication to treat CRPC. Small interfering RNAs have shown great potential as a targeted therapy. This review discusses prostate cancer progression and the role of AR signaling in CRPC, and proposes siRNA-based targeted therapy as a promising strategy for CRPC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据